CHEMERIN AS A POTENTIAL REGULATOR OF MITOCHONDRIAL QUALITY CONTROL IN OBESE PATIENTS
https://doi.org/10.15789/1563-0625-CAA-2227
Abstract
In obese patients, the relationship between the content of chemerin in blood plasma and the expression of genes TFAM, Drp1, MFN2, SOD, BAX, responsible for quality control of mitochondria, in insulin-dependent tissues (adipose tissue, liver) was revealed. The tissue-specific features of gene expression (TFAM, Drp1, MFN2, SOD, BAX), the number of mtDNA copies in the studied depots in obese patients were established. It has been proven that a change (decrease) in the number of mtDNA copies in insulin-dependent tissues can have a protective effect on mitochondria under conditions of increased oxidative stress. It was found that in patients without type 2 diabetes, an increase in chemerin production promotes the activation of the antioxidant system in the visceral adipose tissue but not in the liver. On the contrary, all obese patients with type 2 diabetes showed a decrease (compared with patients without type 2 diabetes) in the plasma level of chemerin. Thus, the low content of chemerin in the blood plasma in patients with type 2 diabetes mediates the formation of mitochondrial dysfunction in insulin-dependent tissues (adipose tissue, liver).
Supporting agencies: The research was supported by the Russian Foundation for Basic Research and Kaliningrad Region (No. 19-415-393004-r_mol_a to Daria Skuratovskaia, 19-44-390005-r_a to Daria Skuratovskaia); State assignment in the field of scientific activity (No. FZWM-2020-0010 to Larisa Litvinova); State Support of Leading Scientific Schools of the Russian Federation (No. 2495.2020.7 to Larisa Litvinova).
About the Authors
M. A. Vulf
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD (Biology), Senior Research Associate, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
D. A. Shunkina (Skuratovskaia)
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD (Biology), Senior Research Associate, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
V. Hung
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
Postgraduate Student, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
A. A. Komar
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
Postgraduate Student, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
P. A. Zatolokin
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD (Medicine), Senior Researcher at the Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
E. V. Kirienkova
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD, MD (Medicine), Senior Research Associate, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
N. D. Gazatova
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD (Biology), Senior Research Associate, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
L. S. Litvinova
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
PhD, MD (Medicine), Director, Center for Immunology and Cellular Biotechnology,
236001, Kaliningrad, Gaidar str., 6, STP “Fabrika”
References
1. Begriche K., Massart J., Robin M.A., Bonnet F., Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013, Vol. 58, no. 4, pp. 1497-1507.
2. Döcke S., Lock J.F., Birkenfeld A.L., Hoppe S., Lieske S., Rieger A., Raschzok N., Sauer I.M., Florian S., Osterhoff M.A., Heller R., Herrmann K., Lindenmüller S., Horn P., Bauer M., Weickert M.O., Neuhaus P., Stockmann M., Möhlig M., Pfeiffer A.F., von Loeffelholz C. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J. Endocrinol., 2013, Vol. 169, pp. 547-557.
3. Horn P., von Loeffelholz C., Forkert F., Stengel S., Reuken P., Aschenbach R., Stallmach A., Bruns T. Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. Sci. Rep., 2018, Vol. 8, pp. 1-9.
4. Koh J.H., Johnson M.L., Dasari S., LeBrasseur N.K., Vuckovic I., Henderson G.C., Cooper S.A., Manjunatha S., Ruegsegger G.N., Shulman G.I., Lanza I.R., Nair K.S. TFAM enhances fat oxidation and attenuates high-fat dietinduced insulin resistance in skeletal muscle. Diabetes, 2019, Vol. 68, pp. 1552-1564.
5. Kwiecien K., Brzoza P., Majewski P., Skulimowska I., Bednarczyk K., Cichy J., Kwitniewski M. Novel insights into the regulation of chemerin expression: role of acute-phase cytokines and DNA methylation. bioRxiv, 2019, pp. 1-24.
6. Picca A., Guerra F., Calvani R., Bucci C., Lo Monaco M.R., Bentivoglio A.R., Coelho-Júnior H.J., Landi F., Bernabei R., Marzetti E. Mitochondrial dysfunction and aging: insights from the analysis of extracellular vesicles. Int. J. Mol. Sci., 2019, Vol. 20 (4), no. 5, pp. 1-12.
7. Shen W., Tian C., Chen H., Yang Y., Zhu D., Gao P., Liu J. Oxidative stress mediates chemerin-induced autophagy in endothelial cells. Free Radic. Biol. Med., 2013, Vol. 55, pp. 73-82.
8. Skuratovskaia D., Komar A., Vulf M., Quang H.V., Shunkin E., Volkova L., Gazatova N., Zatolokin P., Litvinova L. IL-6 reduces mitochondrial replication, and IL-6 receptors reduce chronic inflammation in NAFLD and Type 2 diabetes. Int. J. Mol. Sci., 2021, Vol. 22, pp. 1-15.
9. Skuratovskaia D., Zatolokin P., Vulf M., Mazunin I., Litvinova L. Interrelation of chemerin and TNF-α with mtDNA copy number in adipose tissues and blood cells in obese patients with and without type 2 diabetes. BMC Med. Genomics, 2019, Vol. 12, no. 40, pp. 1-11.
10. Su Z., Nie Y., Huang X., Zhu Y., Feng B., Tang L., Zheng G. Mitophagy in hepatic insulin resistance: therapeutic potential and concerns. Front. Pharmacol., 2019, Vol. 10, no. 1193. pp. 1-15.
11. Takahashi M., Okimura Y., Iguchi G., Nishizawa H., Yamamoto M., Suda K., Kitazawa R., Fujimoto W., Takahashi K., Zolotaryov F.N., Hong K.S., Kiyonari H., Abe T., Kaji H., Kitazawa S., Kasuga M., Chihara K., Takahashi Y. Chemerin regulates β-cell function in mice. Sci Rep., 2011, Vol. 1, pp. 1-10.
12. Vasilenko M.A., Kirienkova E.V., Skuratovskaya D.A., Zatolokin P.A., Mironyuk N.I., Litvinova L.S. The chemerin production changes in obese patients with different carbohydrate metabolism state. Biomed. Khim., 2017, Vol. 63, pp. 582-590.
13. Xie Q., Deng Y., Huang C. Chemerin-induced mitochondrial dysfunction in skeletal muscle. J. Cell. Mol. Med., 2015, Vol. 19, pp. 986-995.
14. Zierath J.R., Livingston J.N., Thörne A., Bolinder J., Reynisdottir S., Lönnqvist F., Arner P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia, 1998, Vol. 41, pp. 1343-1354.
Review
For citations:
Vulf M.A., Shunkina (Skuratovskaia) D.A., Hung V., Komar A.A., Zatolokin P.A., Kirienkova E.V., Gazatova N.D., Litvinova L.S. CHEMERIN AS A POTENTIAL REGULATOR OF MITOCHONDRIAL QUALITY CONTROL IN OBESE PATIENTS. Medical Immunology (Russia). 2021;23(4):881-886. https://doi.org/10.15789/1563-0625-CAA-2227
Views:
477
Email this article 